路透7月3日 - 据在线新闻门户网站Moneycontrol周四援引消息人士的话报导，美国私募股权公司凯雷集团（Carlyle Group CG.O）正准备通过大宗交易出售印度皮拉马尔制药公司（Piramal Pharma PIRM.NS）最多10%的股份。
该报导补充说，这家总部位于美国的私募股权公司可能从此次出售中获得260亿卢比(3.048亿美元) 至270亿卢比的收益。
(1 美元 = 85.3090 印度卢比)
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.